Beta Bionics delays Mint insulin pump launch to Q2 2027, pending FDA clearance

Filed May 21, 2026 · Period ending May 21, 2026 · ~1 min read

Key Changes

• high

  Beta Bionics pushed back full commercialization of its Mint patch insulin pump to end of Q2 2027, subject to FDA clearance of its 510(k) application. The delay reflects FDA feedback on the company's regulatory submission.

  Item 7.01 verify on EDGAR →
• medium

  The updated timeline is based on FDA's initial responses to the Mint ACE insulin pump 510(k) application and progress in scaling manufacturing processes. Company expects manufacturing capacity will meet anticipated demand at launch.

  Item 7.01 verify on EDGAR →